The MYCN oncoprotein as a drug development target

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 125-130

  Lu, Xiaohong ^a   Pearson, Andrew ^b   Lunec, John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Antisense; Cancer therapy; Drug library screening; Luciferase reporter assay; myc; MYC inhibitors; MYC MAX dimerisation; MYCN; Neuroblastoma; Retinoic acid

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY RNA; LUCIFERASE; MAX PROTEIN; NUCLEAR PROTEIN; ORNITHINE DECARBOXYLASE; RETINOIC ACID; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER GROWTH; CANCER INHIBITION; CHICK EMBRYO; CONFERENCE PAPER; DIMERIZATION; DOWN REGULATION; DRUG TARGETING; FIBROBLAST; GENE AMPLIFICATION; GENE CONSTRUCT; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC CONSERVATION; HUMAN; LUNG SMALL CELL CANCER; MITOSIS INHIBITION; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUCLEIC ACID PROBE; ONCOGENE C MYB; ONCOGENE MYC; OUTCOMES RESEARCH; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; REPORTER GENE; RETINOBLASTOMA; RHABDOMYOSARCOMA; TRANSACTIVATION;

EID: 0038105419     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00096-X     Document Type: Conference Paper

References (15)

1. Schor N.F. Neuroblastoma as a neurobiological disease. J. Neurooncol. 41:1999;159-166.
2. Westermann F., Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 184:(2):2002;127-147.
3. Funa K., Steinholtz L., Nou E., Bergh J. Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. Am. J. Clin. Pathol. 88:1987;216-220.
4. Driman D., Thorner P.S., Greenberg M.L., Chilton-MacNeill S., Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer. 73:1994;2231-2237.
5. Mairal A., Pinglier E., Gilbert E., Peter M., Validire P., Desjardins L., Doz F., Aurias A., Couturier J. Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses. Genes Chromosomes Cancer. 28:2000;370-379.
6. Mukherjee B., Morgenbesser S.D., DePinho R.A. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev. 6:1992;1480-1492.
7. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv. Cancer Res. 55:1990;133-270.
8. Lasorella A., Noseda M., Beyna M., Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature. 407:2000;592-598.
9. Facchini L.M., Penn L.Z. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 12:(9):1998;633-651.
10. Xu D., Popov N., Hou M., Wang Q., Bjorkholm M., Gruber A., Menkel A.R., Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA. 98:(7):2001;3826-3831.
11. Roussel M.F., Ashmun R.A., Sherr C.J., Eisenman R.N., Ayer D.E. Inhibition of cell proliferation by the Mad1 transcriptional repressor. Mol. Cell Biol. 16:1996;2796-2801.
12. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K. Small-molecule antagonists of Myc/Max dimerisation inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA. 99:2002;3830-3835.
13. Galderisi U., Di Bernardo G., Cipollaro M., Peluso G., Cascino A., Cotrufo R., Melon M.A.B. Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J. Cell. Biochem. 73:1999;97-105.
14. Matsuo T., Thiele C.J. p27(Kip1): a keg mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene. 16:1998;3337-3343.
15. Balis F.M. Evolution of anticancer drug discovery and the role of cell-based screening. J. Natl. Cancer Inst. 94:2002;78-79.